DS
TTNP

DRW Securities’s Titan Pharmaceuticals TTNP Stock Holding History

DRW Securities’s Portfolio TTNP Stock Details TTNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-21,267
Closed -$102K – 1709
2025
Q3 		$102K Buy
+21,267
New +$93.6K ﹤0.01% 1181

Other funds holding TTNP

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
GWSA
Global Wealth Strategies & Associates Denver, Colorado $528M AUM 23.18% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

DRW Securities's TTNP Position: Q4 2025 in Review

DRW Securities sold out of Titan Pharmaceuticals (TTNP) in Q4 2025, closing a stake of 21,267 shares — an estimated $102K sold.

DRW Securities first reported a position in TTNP in Q3 2025 and held it in 1 quarter. The position peaked at $102K in Q3 2025. 4 funds tracked by Wall St. Rank hold TTNP as of Q4 2025.

  • DRW Securities reported no remaining Titan Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • DRW Securities sold 21,267 Titan Pharmaceuticals shares in Q4 2025, an estimated $102K.
  • DRW Securities first reported a position in Titan Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • DRW Securities's Titan Pharmaceuticals position peaked at $102K in Q3 2025.
  • 4 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.